<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02385487</url>
  </required_header>
  <id_info>
    <org_study_id>S14-01349</org_study_id>
    <nct_id>NCT02385487</nct_id>
  </id_info>
  <brief_title>Inflammation in Type 2 Myocardial Infarction</brief_title>
  <official_title>Inflammation in Type 2 Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Type 2 myocardial infarction (MI) is defined as myocardial necrosis that results from an
      imbalance of myocardial oxygen supply and demand. Although type 2 MI is highly prevalent in
      patients with critical illness and strongly associated with mortality, the pathophysiology
      remains poorly understood. Inflammation is central to the development of atherosclerosis,
      plaque rupture, and other subtypes of MI, but the role of inflammation in type 2 MI and
      myocardial necrosis has not been defined. The investigators aim to to delineate the
      mechanistic role of inflammation in myocardial necrosis and type 2 MI complicating critical
      medical illness.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Logistics and feasibility
  </why_stopped>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Leukocyte-platelet aggregates</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Leukocyte-platelet aggregates</measure>
    <time_frame>Day 10</time_frame>
    <description>Participants will be followed for the duration of hospital stay, an expected average of 10 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monocyte-platelet aggregates</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monocyte-platelet aggregates</measure>
    <time_frame>Day 10</time_frame>
    <description>Participants will be followed for the duration of hospital stay, an expected average of 10 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutrophil-platelet aggregates</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutrophil-platelet aggregates</measure>
    <time_frame>Day 10</time_frame>
    <description>Participants will be followed for the duration of hospital stay, an expected average of 10 days.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>EndoPAT score</measure>
    <time_frame>Day 1</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>EndoPAT score</measure>
    <time_frame>Day 10</time_frame>
    <description>Participants will be followed for the duration of hospital stay, an expected average of 10 days.</description>
  </other_outcome>
  <other_outcome>
    <measure>surface L-selectin</measure>
    <time_frame>Day 1</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>surface L-selectin</measure>
    <time_frame>Day 10</time_frame>
    <description>Participants will be followed for the duration of hospital stay, an expected average of 10 days.</description>
  </other_outcome>
  <other_outcome>
    <measure>soluble L-selectin</measure>
    <time_frame>Day 1</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>soluble L-selectin</measure>
    <time_frame>Day 10</time_frame>
    <description>Participants will be followed for the duration of hospital stay, an expected average of 10 days.</description>
  </other_outcome>
  <other_outcome>
    <measure>surface CD11b</measure>
    <time_frame>Day 1</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>surface CD11b</measure>
    <time_frame>Day 1</time_frame>
    <description>Participants will be followed for the duration of hospital stay, an expected average of 10 days.</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>Myocardial Infarction</condition>
  <condition>Inflammation</condition>
  <condition>Critical Illness</condition>
  <arm_group>
    <arm_group_label>Critical illness and type 2 MI</arm_group_label>
    <description>Critically ill adults with abnormal serum troponin I during hospitalization for critical illness.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Critical illness without type 2 MI</arm_group_label>
    <description>Critically ill adults without an elevation in troponin I complicating critical illness.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Venous blood samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adults admitted to the Medical Intensive or Coronary Care Units (MICU or CCU)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  â‰¥21 years of age

          -  admitted to the Medical Intensive or Coronary Care Units

          -  sepsis or respiratory failure

          -  clinically indicated troponin measurement within 24 hours of ICU admission

        Exclusion Criteria:

          -  unstable angina or Type 1 MI

          -  percutaneous or surgical coronary revascularization within 7 days

          -  heart failure exacerbation

          -  primary valvular disorder

          -  aortic dissection

          -  infiltrative heart disease or hypertrophic cardiomyopathy

          -  myocarditis

          -  pulmonary embolism

          -  electrocardiogram with &gt;1mm ST segment elevation in two consecutive leads

          -  serum cardiac troponin &gt;99th percentile URL but no clear rise or fall pattern

          -  history of chronic inflammatory disease

          -  use of therapeutic-dose anticoagulants / antiplatelet agents other than aspirin

          -  pregnant or incarcerated

          -  enrolled in a competing study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Binita Shah, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bellevue Hospital Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2015</study_first_submitted>
  <study_first_submitted_qc>March 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2015</study_first_posted>
  <last_update_submitted>July 1, 2015</last_update_submitted>
  <last_update_submitted_qc>July 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myocardial Infarction</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Critical Illness</keyword>
  <keyword>Necrosis</keyword>
  <keyword>Sepsis</keyword>
  <keyword>Respiratory Insufficiency</keyword>
  <keyword>Myocardial Ischemia</keyword>
  <keyword>Cardiovascular Diseases</keyword>
  <keyword>Heart Diseases</keyword>
  <keyword>Vascular Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

